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Summary
Background: Cytomegalovirus (CMV) is a chronic infection that is widely distributed in the population. CMV infects a range
of tissues, including endothelium, and viral replication is suppressed by the host immune system. Infection is associated
with increased risk of mortality from vascular disease in older people, but the mechanisms behind this have not been
determined.
Aim: We investigated the association between CMV infection and cardiovascular phenotype in a cohort of healthy elderly
donors.
Design: CMV serostatus and cardiovascular parameters were determined in the Lothian Birth cohort, which comprises 1091
individuals aged 70 years in whom many environmental, biochemical and radiological correlates of vascular function have
been determined.
Methods: CMV serostatus was determined by enzyme-linked immunosorbant assay and correlated with a range of bio-
chemical and phenotypic measures.
Results: Sixty-five percent of participants were CMV seropositive, which indicates chronic infection. The mean sitting sys-
tolic blood pressure (SBP) was 149.2 mmHg in CMV seropositive individuals compared with 146.2 mmHg in CMV seronega-
tive subjects (SD 18.7 vs. 19.7; P<0.017). This association between CMV infection and SBP was not attenuated after adjust-
ment for a wide range of biological and socio-economic factors.
Conclusions: These data show that CMV infection is associated with an increase in SBP in individuals at age 70 years. The
magnitude is comparable to environmental variables such as obesity, diabetes or high salt intake. This is the first evidence
to show that a chronic infection may be an important determinant of blood pressure and could have significant implications
for the future management of hypertension.
Received: 23 August 2015; Revised (in revised form): 31 January 2016
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which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Introduction
Cytomegalovirus (CMV) is a member of the human herpesvirus
family and is widely distributed in the population.1 Like all her-
pes viruses, CMV establishes a state of chronic infection, and
viral replication must be suppressed by the host immune re-
sponse. CMV is a significant cause of morbidity in immunosup-
pressed patients but may also be associated with clinical
complications in the immune competent population. CMV in-
fection appears to carry particular significance for older adults,
and infection has been associated with an increased rate of
mortality in several studies.2–5 A particular association is with
cardiovascular disease and the risk of vascular mortality has
been shown to be nearly doubled in some studies.3 The mech-
anism behind this correlation is unclear although the virus can
infect a wide range of cell types including endothelial and vas-
cular smooth muscle cells.
Atherosclerosis is the major cause of vasculo-occlusive
events such as myocardial infarction, but there remains debate
as to whether or not CMV infection acts as a risk factor for the
development of this pathology.6 In contrast, the virus has been
associated with the development of arteriosclerosis in patients
with renal disease.7 Arteriosclerosis is a disease of the arterial
media layer in which increased collagen content, together with
calcification, hyperplasia and hypertrophy of vascular smooth
muscle cells, leads to arterial wall hypertrophy and increased
arterial stiffness.7 Arteriosclerosis is characterized by an in-
crease in systolic blood pressure (SBP). In this study, we investi-
gated whether CMV infection was associated with an increase
in blood pressure in a large healthy population at age 70 years.
Methods
The LBC1936 study consists of 1091 relatively healthy age-
homogeneous older people who participated in the Scottish
Mental Survey of 1947 when aged 11 years. The participants
have undergone extensive phenotypic and genetic investigation
following recruitment, and the cohort has been described previ-
ously in detail.8 In particular, at age 70 years, participants
underwent a series of cognitive tests, as well as physical and
biochemical investigations. Participants were Caucasian, gave
written informed consent and almost all lived independently in
the Lothian region of Scotland. The data available for partici-
pants were mostly complete and where variables were missing
this is stated in Table 1.
Systolic and diastolic blood pressures were measured on
three occasions both sitting and standing using a validated
oscillometric Omron 705IT monitor.8 Briefly, participants were
seated in a relaxed environment for up to 15 min prior to meas-
urement and with their arm outstretched and supported.
Measurements were performed in triplicate. Results are pre-
sented as the average of the second and third readings.
Standing blood pressure was also assessed. All analyses were
also repeated using the average of all three readings and for the
individual readings.
Blood samples were taken for basic biochemistry and other
measures including glycated haemoglobin (HbA1c), estimated
glomerular filtration rate, thyroxine (T3, T4), albumin, choles-
terol and C-reactive protein.8
Ankle Brachial Pressure Index (ABPI) and carotid intima
thickness (intima-media thickness [IMT]) in the common ca-
rotid artery and carotid bulb and the maximum degree of any
atheromatous stenosis were measured at age 73 years in a sub-
set of individuals as previously described.9
Determination of CMV seroprevalence
CMV was measured in plasma samples collected at age 70 years
using a CMV enzyme-linked immunosorbant assay as previ-
ously reported.10 Briefly, mock and viral-infected lysate was
coated onto enzyme-linked immunosorbant assay plates and
plasma samples added in duplicate to plates before washing
and addition of secondary antibody and substrate. Data were
analysed in PRISM, and CMV titre was calculated with reference
to a standard curve. Values above 10 were considered to be
seropositive.
Statistical analysis
All data were analysed using SPSS version 21.0 (SPSS Inc,
Chicago, IL). Normally distributed continuous data are pre-
sented as mean and standard deviation with comparisons
made using Student’s t-test or one-way analysis of variance.
Non-normally distributed data such as C-reactive protein are
presented as median (interquartile range) and analysed using
Mann–Whitney U or the Kruskal–Wallis test. Categorical data
are presented as percentage and analysed using the chi-squared
test. All the variables used in the analyses had<5% of the values
missing and were therefore treated as missing completely at
random with case-wise deletion. Linear regression analysis was
used to assess the univariable and multivariable relationship
between outcomes and parameters under investigation. A type
1 error below 5% (P< 0.05) was considered statistically
significant.
Results
CMV infection is present in the majority of participants
The study analysed 1091 participants of the Lothian Birth
Cohort (1936), of which 37 had to be excluded due to missing
CMV infection data (n¼ 30) or incomplete blood pressure meas-
urements (n¼ 7). The demographic characteristics of the re-
maining 1054 study population are listed in Table 1. In total, 689
(64.5%) of the cohort were CMV seropositive and, as previously
described, were more likely to be female, have lower mini-men-
tal state scores, live in more overcrowded housing at age 11
years, be less likely to have access to indoor toilet facilities at
age 11 years, their father’s occupation tended to be more man-
ual in nature and they had fewer years of education.11 CMV in-
fection was not associated with incidence of diabetes, smoking
status or BMI. There were no differences in recorded haematolo-
gical or biochemical variables. CMV infection did not influence
the self-reported incidence of stroke or myocardial infarction.
CMV infection is associated with an increase in SBP
We next went on to examine the association between CMV in-
fection and systolic and diastolic blood pressure within study
participants (Table 2). CMV seropositive subjects had a higher
mean SBP and this effect was apparent when either sitting or
standing. The mean systolic pressure while sitting was
149.2 mmHg in those with CMV infection compared with
146.2 mmHg in subjects without infection (SD 18.7 vs. 19.7;
P¼ 0.017) (Figure 1). An increment in systolic pressure of
2.7 mmHg was observed in the standing systolic pressures,
which were measured at 148.3 mmHg and 145.6 mmHg, respect-
ively (SD 18.9 vs. 20.7; P¼ 0.032). The sitting diastolic blood pres-
sure was over 1 mmHg higher in CMV seropositive individuals,
but this value did not reach statistical significance.
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Arteriosclerosis is associated with a decrease in vessel
elasticity and this can be manifest as an increase in the arter-
ial pulse pressure. We therefore examined the impact of CMV
infection on pulse pressure and mean arterial pressure (MAP).
CMV infection was associated with a non-significant
1.9 mmHg increase in pulse pressure, and this was observed
when subjects were either sitting or standing. The MAP is the
average arterial pressure during a single cardiac cycle and is
calculated as the diastolic blood pressure added to one third of
the pulse pressure. The MAP was increased by 1.7 mmHg in
the CMV seropositive group to reach a value of 103.8 mmHg
compared to 102.1 mmHg in the CMV seronegative partici-
pants (SD 11.6 vs. 12.3; P¼ 0.027).
In order to examine the potential importance of CMV infec-
tion on the development of atherosclerosis, we determined
the association between infection status and both IMT and
ABPI measurements. These values are widely used as indica-
tors of atheroma load and no differences were seen in carotid
IMT (P¼ 0.297), maximum carotid artery stenosis (P¼ 0.527) or
ABPI (P¼ 0.401) between CMV seropositive and seronegative
subjects.
CMV infection is an independent determinant of SBP
Univariable and multivariable linear regression analyses were
used to assess the relative importance of CMV infection on SBP.
CMV infection was associated with SBP in univariable analysis
(B¼ 2.95; 95% confidence interval [CI]: 0.53–5.37; P¼ 0.017) but
was not associated with diastolic pressure (1.07; 95% CI: 0.001–
0.005; P¼ 0.108). Other factors associated significantly with SBP
in univariable analysis were age, gender, diabetes, haemoglo-
bin, haematocrit, albumin, cholesterol and calcium. None of the
markers of socioeconomic status that were associated with
CMV infection were associated with SBP. CMV infection and the
additional factors associated with SBP were then entered into a
multivariable regression model. CMV infection remained posi-
tively associated with sitting SBP (B¼ 3.14; P¼ 0.011; 95% CI:
0.73–5.54).
Table 1. Clinical and demographic characteristics of the Lothian Birth Cohort divided according to CMV serostatus
Mean (SD)/percentages CMV negative, mean (SD) CMV positive, mean (SD)
CMV serostatus (%) 35.5 64.5
Gender, male (%)* 50.6 57.8 46.7
Age (years) 69.6 (0.83) 69.5 (0.88) 69.6 (0.81)
Smoking (current) (%) 13.2 15.3 12.0
BMI (kg/m2) 27.8 (4.35) 27.7 (4.12) 27.8 (4.43)
History of stroke (%) 5.0 5.2 4.9
Diabetes mellitus (%) 8.3 6.8 9.1
eGFR (ml/min/1.73 m2) n¼ 1049 82.2 (17.05) 82.3 (17.50) 82.2 (16.82)
Haemoglobin (g/l) n¼ 1049 145.2 (13.0) 146.1 (12.54) 144.7 (13.5)
HbA1c (total %) n¼1048 5.9 (0.77) 5.9 (0.73) 6.0 (0.79)
Triglyceride (mmol/l) n¼ 960 1.6 (0.92) 1.6 (0.80) 1.7 (0.97)
Total cholesterol (mmol/l), n¼ 1049 5.5 (1.16) 5.4 (1.19) 5.5 (1.14)
Calcium (mmol/l), n¼1044 2.3 (0.10) 2.3 (0.09) 2.3 (0.10)
C-reactive protein (mg/l), n¼ 1041 3.0 (4.50) 3.0 (4.50) 3.0 (4.50)
Figures are mean (standard deviation) for continuous variables, apart from C-reactive protein, which is presented as median (interquartile range) due to non-normal
distribution. Categorical variables are presented as percentages, and for disease status, these represent the percentage of individuals reporting the disease. To assess
differences between the CMV negative and positive groups, continuous variables were analysed by t-test or Mann–Whitney U test. Categorical variables were analysed
by Chi-square. n¼1054 unless otherwise stated.
*P<0.05.
Table 2. Cardiovascular measurements in relation to presence of CMV infection
Mean (SD) CMV negative, mean (SD) CMV positive, mean (SD)
SBP (sitting)* 148.2 (19.10) 146.2 (19.71) 149.2(18.68)
SBP (standing)* 147.4 (19.58) 145.6 (20.66) 148.3 (18.93)
Diastolic blood pressure (sitting) 80.73 (10.30) 80.0 (10.36) 81.10 (10.26)
Diastolic blood pressure (standing) 84.9 (10.50) 84.3 (10.45) 85.2 (10.52)
Pulse pressure (sitting) 67.4 (15.14) 66.2 (15.04) 68.1 (15.17)
Pulse pressure (standing) 62.5 (15.48) 61.3 (15.20) 63.2 (15.60)
MAP (sitting)* 103.2 (11.88) 102.1 (12.28) 103.8 (11.63)
Pulse pressure/MAP (sitting) 0.65 (0.13) 0.65 (0.12) 0.66 (0.13)
ABPI 1.10 (0.18) 1.10 (0.18) 1.10 (0.18)
IMT (mm, right) 0.83 (0.22) 0.84 (0.24) 0.83 (0.20)
IMT (mm, left) 0.86 (0.25) 0.87 (0.26) 0.86 (0.24)
Carotid arteries maximum stenosis (%, right) 14.1 (15.65) 14.7 (15.43) 13.7 (15.79)
Carotid arteries maximum stenosis (%, left) 12.7 (14.89) 11.1 (12.74) 13.6 (15.85)
Figures are mean (standard deviation). All blood pressures are measured in mmHg. Pulse pressure (PP) was defined as SBP  diastolic blood pressure. MAP was calcu-
lated as diastolic blood pressureþ1/3 PP. Differences between CMV negative and CMV positive groups were analysed by t-test. n¼ 1054, with the exception of ABPIs,
IMT and carotid stenosis, which were measured in 736, 798 and 506 subjects, respectively.
*P<0.05.
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Assessment of CMV infection in relation to gender and
medication status
Gender differences have been observed in relation to both the
overall prevalence of CMV infection and the magnitude of the
CMV-specific immune response within infected individuals.1,12
Therefore, it was important to consider the influence of gender
and CMV upon blood pressure (Supplementary Table S1). Data
were also available regarding whether participants were taking
medication to lower blood pressure. Thirty-eight percent (262/
689) of CMV seropositive individuals were taking anti-hyperten-
sive treatment compared to 33% (120/365) of the CMV seronega-
tive cohort (P¼ 0.098).
The increment in sitting SBP in association with CMV infec-
tion was particularly marked (6.9 mmHg) in women who were
not taking anti-hypertensive medication. However, caution
must be applied during analysis of subgroups, and a statistical
model was therefore applied to determine if medication status
or gender influenced the relationship between CMV serostatus
and blood pressure. This model included CMV status, gender
and medication status and both medication (B¼ 0.16, SE 0.06,
P¼ 0.0125) and CMV serostatus (B¼ 0.15, SE 0.06, P¼ 0.01) were
found to be associated with SBP (Supplementary Figures S1 and
S2). However, there were no interactions between these three
factors (P¼ 0.07–0.19) and as such the influence of CMV on blood
pressure was not stronger in people taking medication or in re-
lation to gender.
No association is observed between CMV-specific IgG
antibody titre and SBP
The titre of the CMV-specific antibody response within CMV
seropositive individuals has been linked to mortality and mor-
bidity risk in several studies.2,4 In our cohort, CMV-specific IgG
titres were higher in female compared to male participants (1.69
vs. 1.63; P 0.0001). However, no significant association was
seen between antibody titre and either systolic sitting (P¼ 0.16)
or standing (P¼ 0.22) blood pressure. There was also no signifi-
cant association when groups were split into male (P¼ 0.19) or
female participants (P¼ 0.46).
Discussion
CMV infection is associated with frailty and an increased risk
of mortality in older individuals and a number of potential
mechanisms have been invoked to explain this.2,13,14 These in-
clude immune senescence due to accumulation of large popu-
lations of virus-specific memory T cells or an increase in
systemic inflammation.15–18 However, vascular disease is the
most important pathology observed in association with CMV
infection in these settings and the mechanism remains largely
unknown. Our study shows that CMV infection is associated
with an increase in SBP in healthy older individuals. In those
patients who were not taking anti-hypertensive medication,
systolic pressure was 4 mmHg higher in CMV seropositive indi-
viduals. The sitting diastolic pressure was 1 mmHg higher and
this pattern would be consistent with the pathology of arterio-
sclerosis in which the development of vessel stiffness leads to
a relative increase in pulse pressure.19 Such a process is likely
to be sufficient to explain much of the association between
CMV infection and increased risk of vascular death. Indeed, ar-
terial stiffness is a powerful prognostic significance for cardio-
vascular disease as the failure to buffer intermittent left
ventricular ejection into the arterial system results in left
ventricular hypertrophy and fibrosis, cerebrovascular disease
and renal damage.20
A number of biological mechanisms may be invoked to ex-
plain our observation, as the virus has a broad tropic capacity
and can infect a wide variety of cells including endothelial and
smooth muscle cells.21 Viral protein can be detected within aor-
tic endothelial cells, and arteries may potentially serve as sites
of both latent and lytic infection.22 Vascular pathology might
occur either directly from lytic viral infection or from secondary
immunopathology resulting from the immune response against
infected tissue.23 Indeed, the majority of CMV-specific T cells
are located within peripheral blood and are unique within
virus-specific T cells in that they express the CX3CR1 chemo-
kine receptor that targets them to fractalkine on endothelium.24
Arteriosclerosis is associated with increased arterial vessel stiff-
ness and its clinical associations include heart failure and
increased risk of vascular mortality.25 The pathology is also a
dominant pathological feature of the vascular complications of
renal disease and CMV infection is well documented risk factor
for vascular disease in this setting. Indeed, recent work has
identified CMV infection as a direct correlate of arteriosclerosis
in this population and infection was associated with increased
arterial stiffness as determined by aortic pulse wave velocity
and decreased distensibility of the proximal ascending and des-
cending aorta.7
An increase in murine blood pressure has been reported fol-
lowing murine CMV infection (MCMV) and was also found to be
independent of the development of atherosclerosis.
Interestingly, MCMV infection was shown to increase renin ex-
pression from the renal cells suggesting that an increase blood
volume may contribute to this effect.26 Suggestions that CMV
infection can lead to an increase in blood pressure have also
been seen in human studies. Li et al.27 reported a correlation be-
tween the level of an HCMV-associated miR-UL112 and essen-
tial hypertension. In addition, a 1 mmHg increase in SBP was
observed in a subgroup of men aged 24–39 years with elevated
titres of CMV-specific antibody.28 This latter observation is intri-
guing as many determinants of poor health have been associ-
ated with individuals with the highest quartile of CMV-specific
antibody.2 However, our own observations reveal a strong asso-
ciation between CMV infection alone and SBP, irrespective of
the magnitude of the CMV-specific immune response.
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Figure 1. Blood pressure in relation to CMV serostatus within the study cohort.
Mean diastolic pressure (DBP) and systolic pressure (SBP) were determined while
sitting or standing in relation to CMV serostatus (n¼1054). *P0.05.
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Moreover, we are able to define the magnitude of this effect in
older adults.
An increase in systolic pressure of 3 mmHg is of marked clin-
ical significance at a population level. An increase of only
2 mmHg is associated with a 7% increased risk of mortality from
ischaemic heart disease and a 10% increased risk of mortality
from stroke.29 Similar increments are typical of those associated
with major risk factors for hypertension such as high salt intake,
obesity or diabetes. The increase in blood pressure would also act
as a risk factor for the development of atheroma and could ex-
plain some reports, which indicate an association between CMV
infection and increased risk of ischaemic heart disease.30
No increase was observed in the incidence of vascular compli-
cations in relation to CMV infection in this cohort. It is likely that
this reflects the relatively low prevalence of these events in the
population to date. The Lothian cohort is a relatively healthy
group and vascular events have proven uncommon by age 70
years. For example, 24.8% of the cohort reported a history of car-
diovascular disease and 5% reported stroke. The prevalence of
diabetes was 9.1% within CMV seropositive individuals compared
to 6.8% in the uninfected group, but this difference was not statis-
tically significant. Indeed, there is no evidence that CMV infection
can increase the risk of development of diabetes, although the
potential importance of CMV infection in established diabetes is
revealed by the increased incidence of vascular complications in
diabetic patients with elevated numbers of CD4þCD28- T cells,
an established correlate of CMV infection.31,32
CMV infection is more common in women, possibly due to
an increased exposure to infants and children with recent CMV
infection.33 Analysis of CMV-specific IgG titre in our cohort also
demonstrated that titres were significantly higher in women,
which may potentially reflect an increased viral load. Our data
reveal a trend towards a higher SBP in CMV seropositive
women, although this did not reach statistical significance. This
observation should be tested in larger cohorts, but a potential
association between gender, antibody titre and blood pressure
would suggest that viral load or immunopathology may directly
underlie the acceleration of arteriosclerosis.
Hypertension is one of the greatest challenges in modern
clinical practice and, to our knowledge, our data are the clearest
reported association between an infection and an increase in
blood pressure. The observation that a common infection
makes an important contribution to SBP offers the potential for
new forms of prevention or treatment in the management of
hypertension. Immunization regimens to prevent primary CMV
infection are showing significant promise and offer the prospect
of a vaccine to reduce the prevalence of hypertension. For those
with established infection, it is even possible that anti-viral or
anti-inflammatory medications may come to be valuable add-
itions to the current lexicon of anti-hypertensive drugs.
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